However, anti-angiogenic drugs, such as anti-VEGF, have been tested for some time in clinical trials to suppress blood supply to the tumor and showed limited success for several reasons, e.g., because hypoxia was induced that then fueled cancer progression (122). This evidence concerns the gene VEGFA and cancer.